Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers

Zheng, XJ; Gu, HF; Cao, XP; Pan, BY; Xiang, HL; Ju, MX; Xu, SJ; Zheng, M

Zheng, M (通讯作者)，Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Gynecol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China.

FRONTIERS IN IMMUNOLOGY, 2023; 14 ():

Abstract

BackgroundTislelizumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody engineered to minimize binding to Fc gamma receptors. It has been......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索